# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of nove...
Truist Securities analyst Joon Lee maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and maintains $120 price target.
Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress ...
Raymond James analyst Steven Seedhouse reiterates Viking Therapeutics (NASDAQ:VKTX) with a Strong Buy.